Cigli State Hospital, Department of Gastroenterology, Izmir, Turkey.
Medicalpark Izmir Hospital, Department of Hematology, Izmir, Turkey.
Afr Health Sci. 2022 Sep;22(3):561-566. doi: 10.4314/ahs.v22i3.60.
Hepatitis B infection is an important problem in immune suppressed patients. Anti HbcAb is an important marker that shows past exposure to virus. In this study, we retrospectively searched HBV serology among the patients who had Bone Marrow Transplantation (BMT) or chemotherapies (CT) at Medicalpark Izmir Hospital Bone Marrow Transplantation Unit; changes in viral parameters throughout therapy; and tried to find the efficiency of antiviral prophylaxis.
We retrospectively evaluated the viral parameters; HbsAg, Anti HbsAb, Anti Hbc IgG, HbeAg, Anti Hbe Ab, HBV DNA, HCV RNA which were carried out before BMT and CT. We grouped the patients as latent HBV infection and inactive carriers. Started antiviral treatment as prophylaxis, monitored the changes in serological parameters and defined HBV related situations.
A total of 584 patients were evaluated retrospectively. Twenty patients were having latent HBV infection. Ten patients were inactive carriers of HBV. In post-transplant period, the patients were screened for 11 months (1-38 months). None of the patients experienced HBV activation during follow period.
The best approach in HbcAb positive patients with planned immunosuppressive treatment is the use of anti-viral agents before immune suppression and close monitoring of the patients HBV-related markers.
乙型肝炎病毒（HBV）感染是免疫抑制患者的一个重要问题。抗-HBcAb 是既往病毒暴露的重要标志物。本研究回顾性分析了伊兹密尔医疗公园骨髓移植中心接受骨髓移植（BMT）或化疗（CT）的患者的 HBV 血清学；治疗过程中病毒参数的变化；并试图寻找抗病毒预防的效果。
我们回顾性评估了 HBsAg、抗-HBsAb、抗-HBc IgG、HBeAg、抗-HBeAb、HBV DNA、HCV RNA 等病毒参数，这些参数在 BMT 和 CT 前进行了检测。我们将患者分为潜伏性 HBV 感染和非活动性携带者。作为预防措施开始抗病毒治疗，监测血清学参数的变化，并明确 HBV 相关情况。
共回顾性评估了 584 例患者。20 例患者存在潜伏性 HBV 感染，10 例患者为 HBV 非活动性携带者。在移植后期间，对患者进行了 11 个月（1-38 个月）的筛查。在随访期间，没有患者出现 HBV 激活。
对于计划接受免疫抑制治疗且 HbcAb 阳性的患者，最好在免疫抑制前使用抗病毒药物，并密切监测患者的 HBV 相关标志物。
